Inari Medical today released information on a new $6.1 million equity funding round to support its business and thrombectomy system, according to an SEC filing.
Inari produces the FlowTriever thrombectomy system, which is an FDA approved catheter-based thrombectomy device designed to remove clots in the peripheral vasculature, Inari Medical said.
The device won FDA 510(k) approval in February and was used to treat its 1st patient in March, the company said.
The money comes from 5 anonymous sources, according to the SEC filing, and while the company has received all the funds it was seeking in the round, it has not disclosed how it plans to spend the newly raised funds.
In June, Inari Medical said it closed a $12.4 million Series B financing round to fund continued product development and studies of its FlowTriever thrombectomy system.
The round was led by members of the board of directors and returning Versant Ventures and U.S. Venture Partners, as well as several medical device industry veterans, the Irvine, Calif.-based company said.